MTEC member develops treatment for COVID-19 gastrointestinal symptoms

MTEC Success Story

Editor’s Note: This post is part of a COVID-19 success stories series. 

Many know or have heard about the respiratory symptoms associated with COVID-19. Lesser known is that the virus also attacks the lining of the gastrointestinal (GI) tract, causing infections that may persist even after the respiratory symptoms have resolved, contributing to what’s known as “long-haul COVID.” With support from USAMRDC’s Military Infectious Diseases Research Program (MIDRP) and the Medical Technology Enterprise Consortium (MTEC), Lumen Bioscience is developing  a low-cost, orally delivered cocktail of antibodies against SARS-CoV-2 (the virus that causes COVID-19) to prevent and treat infection of the gastrointestinal (GI) tract.

Lumen Bioscience, a nontraditional government contractor and small business, has completed several milestones culminating in a cocktail of high-potency antibodies that neutralize SARS-CoV-2. Early results demonstrate strong resistance to GI proteases and high-yield in Lumen’s unique ultra-low-cost cGMP manufacturing system. A gastrointestinal targeted therapy could reduce overall viral burden, inhibit disease progression, accelerate viral clearance, and block significant transmission routes. By encouraging participation from nontraditional organizations such as Lumen Bioscience, the OTA collaboration model is facilitating the development of this GI treatment.

About MTEC

MTEC seeks to accelerate the delivery of technology and medical solutions that prevent and treat injuries and restore America’s military and veterans to full health.

author avatar
ADMIN_DEMO5

continue reading

Related Posts

  • 259 words1.3 min read

    The Maritime Sustainment Technology and Innovation Consortium (MSTIC) has recently reached a significant milestone, welcoming Snowbird Technologies as its 500th member.

  • author avatar
    christine.quinn@ATI.ORG
  • 175 words0.9 min read

    MTEC member and small business SurgiBox Inc. is an inventor of surgical kits that allow doctors to perform life-saving surgeries anywhere – even in the middle of war zones or other hostile situations.

  • author avatar
    christine.quinn@ATI.ORG
  • 282 words1.5 min read

    The very first award made through the Maritime Sustainment Technology Innovation Consortium (MSTIC) Other Transaction Agreement (OTA) with the Naval Surface Warfare Center, Philadelphia Division (NSWCPD) has completed final testing with successful results. 

  • author avatar
    christine.quinn@ATI.ORG
author avatar
ADMIN_DEMO5